

Leptin Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/L1AD6D1AD287EN.html>

Date: June 2020

Pages: 54

Price: US\$ 3,500.00 (Single User License)

ID: L1AD6D1AD287EN

Abstracts

Leptin Receptor - Pipeline Review, H1 2020

SUMMARY

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 8 molecules. The latest report Leptin Receptor – Pipeline Review, H1 2020, outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) – Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexigenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The molecules developed by companies in Phase II and Preclinical stages are 1 and 7 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Alzheimer's Disease, Choroidal Neovascularization, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects

The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leptin Receptor (HuB219 or

OB Receptor or CD295 or LEPR) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in
Therapeutics Development

Allysta Pharmaceuticals Inc

Arreus Inc

Celllivery Therapeutics Inc

Jyant Technologies Inc

NeuroNano Pharma Inc

Neurotez Inc

Regeneron Pharmaceuticals Inc

XL-protein GmbH

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles

Allo-Aca - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARV-1802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-08 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

[Leptin Receptor \(HuB219 or OB Receptor or CD295 or LEPR\) - Dormant Products](#)

[Leptin Receptor \(HuB219 or OB Receptor or CD295 or LEPR\) - Discontinued Products](#)

[Leptin Receptor \(HuB219 or OB Receptor or CD295 or LEPR\) - Product Development](#)

[Milestones](#)

[Featured News & Press Releases](#)

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Allysta Pharmaceuticals Inc, H1 2020

Pipeline by Arrevus Inc, H1 2020

Pipeline by Cellivery Therapeutics Inc, H1 2020

Pipeline by Jyant Technologies Inc, H1 2020

Pipeline by NeuroNano Pharma Inc, H1 2020

Pipeline by Neurotez Inc, H1 2020

Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Pipeline by XL-protein GmbH, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Allysta Pharmaceuticals Inc

Arreus Inc

Cellivery Therapeutics Inc

Jyant Technologies Inc

NeuroNano Pharma Inc

Neurotez Inc

Regeneron Pharmaceuticals Inc

XL-protein GmbH

I would like to order

Product name: Leptin Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/L1AD6D1AD287EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L1AD6D1AD287EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970